Summit Therapeutics
SMMT
91 hedge funds and large institutions have $37.1M invested in Summit Therapeutics in 2023 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 34 increasing their positions, 11 reducing their positions, and 7 closing their positions.
429% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 7
209% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 11
49% more funds holding
Funds holding: 61 → 91 (+30)
36% more call options, than puts
Call options by funds: $2.22M | Put options by funds: $1.64M
7% more capital invested
Capital invested by funds: $34.6M → $37.1M (+$2.51M)
1% less ownership
Funds ownership: 4.03% → 3.02% (-1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$11.7M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.84M |
| 3 |
BlackRock
New York
|
+$3.57M |
| 4 |
Millennium Management
New York
|
+$2.47M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$1.12M |
| 2 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$531K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$379K |
| 4 |
KI
Kapitalo Investimentos
Sao Paulo,
Brazil
|
-$243K |
| 5 |
6CM
683 Capital Management
New York
|
-$216K |
SMMT Hedge Fund Activity: Q1 2023 in Review
91 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q1 2023, worth a combined $37.1M — up 7.3% from $34.6M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new SMMT positions and 7 closed out — a net gain of 30 holders — while 34 added to existing stakes and 11 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $11.7M. The largest seller was Marshall Wace, cutting an estimated $1.12M.
- 91 institutional investors held Summit Therapeutics (SMMT) as of Q1 2023, up from 61 in Q4 2022.
- Funds reported $37.1M of Summit Therapeutics stock for Q1 2023, up 7.3% quarter-over-quarter.
- 37 funds opened new Summit Therapeutics positions in Q1 2023 and 7 closed out, a net change of +30 holders.
- The largest Summit Therapeutics buyer in Q1 2023 was Baker Bros. Advisors, an estimated $11.7M added.
- The largest Summit Therapeutics seller in Q1 2023 was Marshall Wace, an estimated $1.12M sold.
Based on aggregated 13F filings for Q1 2023.